Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma

Br J Haematol. 2016 Jan;172(2):290-3. doi: 10.1111/bjh.13480. Epub 2015 May 5.

Authors

Peter Ugocsai¹, Daniel Wolff¹, Karin Menhart², Dirk Hellwig², Ernst Holler¹, Wolfgang Herr¹, Albrecht Reichle³

Affiliations

¹ Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
² Department of nuclear Medicine, University Hospital of Regensburg, Regensburg, Germany.
³ Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany. albrecht.reichle@ukr.de.

PMID: 25944562
DOI: 10.1111/bjh.13480

No abstract available

Keywords: biomodulatory therapy; everolimus; metronomic therapy; pioglitazone; refractory Hodgkin lymphoma.

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brentuximab Vedotin
Drug Administration Schedule
Female
Hodgkin Disease / drug therapy*
Humans
Immunoconjugates / administration & dosage
Immunologic Factors / administration & dosage
Male
Positron-Emission Tomography
Remission Induction
Salvage Therapy / methods

Substances

Immunoconjugates
Immunologic Factors
Brentuximab Vedotin